Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 59.43
NAS:EXAS's Cash to Debt is ranked higher than
68% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.29 vs. NAS:EXAS: 59.43 )
Ranked among companies with meaningful Cash to Debt only.
NAS:EXAS' s Cash to Debt Range Over the Past 10 Years
Min: 12.24  Med: No Debt Max: No Debt
Current: 59.43
Equity to Asset 0.90
NAS:EXAS's Equity to Asset is ranked higher than
93% of the 192 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.59 vs. NAS:EXAS: 0.90 )
Ranked among companies with meaningful Equity to Asset only.
NAS:EXAS' s Equity to Asset Range Over the Past 10 Years
Min: -0.41  Med: 0.72 Max: 0.96
Current: 0.9
-0.41
0.96
F-Score: 4
Z-Score: 22.48
M-Score: -1.33
WACC vs ROIC
9.02%
-615.31%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -218.61
NAS:EXAS's Operating margin (%) is ranked lower than
79% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.14 vs. NAS:EXAS: -218.61 )
Ranked among companies with meaningful Operating margin (%) only.
NAS:EXAS' s Operating margin (%) Range Over the Past 10 Years
Min: -5591.71  Med: -420.54 Max: 1150.29
Current: -218.61
-5591.71
1150.29
Net-margin (%) -216.45
NAS:EXAS's Net-margin (%) is ranked lower than
79% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.64 vs. NAS:EXAS: -216.45 )
Ranked among companies with meaningful Net-margin (%) only.
NAS:EXAS' s Net-margin (%) Range Over the Past 10 Years
Min: -5564.4  Med: -403.8 Max: 1123.53
Current: -216.45
-5564.4
1123.53
ROE (%) -53.53
NAS:EXAS's ROE (%) is ranked lower than
73% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.49 vs. NAS:EXAS: -53.53 )
Ranked among companies with meaningful ROE (%) only.
NAS:EXAS' s ROE (%) Range Over the Past 10 Years
Min: -505.37  Med: -54.42 Max: -26.92
Current: -53.53
-505.37
-26.92
ROA (%) -47.94
NAS:EXAS's ROA (%) is ranked lower than
72% of the 213 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.98 vs. NAS:EXAS: -47.94 )
Ranked among companies with meaningful ROA (%) only.
NAS:EXAS' s ROA (%) Range Over the Past 10 Years
Min: -95.07  Med: -45.09 Max: -18.9
Current: -47.94
-95.07
-18.9
ROC (Joel Greenblatt) (%) -483.13
NAS:EXAS's ROC (Joel Greenblatt) (%) is ranked lower than
75% of the 212 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -9.85 vs. NAS:EXAS: -483.13 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NAS:EXAS' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -3463.3  Med: -1718.22 Max: -483.13
Current: -483.13
-3463.3
-483.13
Revenue Growth (3Y)(%) 82.90
NAS:EXAS's Revenue Growth (3Y)(%) is ranked higher than
97% of the 140 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.50 vs. NAS:EXAS: 82.90 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NAS:EXAS' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -17.6 Max: 302.1
Current: 82.9
0
302.1
EBITDA Growth (3Y)(%) 23.50
NAS:EXAS's EBITDA Growth (3Y)(%) is ranked higher than
84% of the 127 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.80 vs. NAS:EXAS: 23.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NAS:EXAS' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -39.4  Med: -13 Max: 46.1
Current: 23.5
-39.4
46.1
EPS Growth (3Y)(%) 24.80
NAS:EXAS's EPS Growth (3Y)(%) is ranked higher than
81% of the 118 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.00 vs. NAS:EXAS: 24.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NAS:EXAS' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -43.1  Med: -15.6 Max: 46.5
Current: 24.8
-43.1
46.5
» NAS:EXAS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

EXAS Guru Trades in Q4 2015

Jim Simons 12,160 sh (New)
Steven Cohen 2,468,828 sh (+20473.57%)
PRIMECAP Management 3,096,300 sh (+13.16%)
» More
Q1 2016

EXAS Guru Trades in Q1 2016

Paul Tudor Jones 19,436 sh (New)
Jim Simons 210,100 sh (+1627.80%)
PRIMECAP Management 4,516,300 sh (+45.86%)
Steven Cohen 747,500 sh (-69.72%)
» More
Q2 2016

EXAS Guru Trades in Q2 2016

Columbia Wanger 770,000 sh (New)
Joel Greenblatt 17,669 sh (New)
PRIMECAP Management 4,516,300 sh (unchged)
Jim Simons Sold Out
Paul Tudor Jones Sold Out
Steven Cohen 507,175 sh (-32.15%)
» More
Q3 2016

EXAS Guru Trades in Q3 2016

Paul Tudor Jones 32,756 sh (New)
Jim Simons 365,300 sh (New)
Joel Greenblatt 53,252 sh (+201.39%)
Steven Cohen Sold Out
PRIMECAP Management 4,491,300 sh (-0.55%)
Columbia Wanger 558,434 sh (-27.48%)
» More
» Details

Insider Trades

Latest Guru Trades with EXAS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:NAS:MEDP, NAS:AXDX, NAS:ABAX, NAS:MYGN, NAS:ALOG, NAS:KANG, NAS:GHDX, NAS:NEOG, NAS:FMI, NAS:QDEL, OTCPK:CZMWY, NAS:NEO, NAS:VIVO, NYSE:ARA, NAS:INCR, NAS:NTRA, NAS:BEAT, NAS:NRCIA, NAS:NVDQ, NAS:HSKA » details
Traded in other countries:EXK.Germany,
Exact Sciences Corp is a molecular diagnostics company currently focused on the early detection and prevention of colorectal cancer. It has developed a non‑invasive, patient friendly screening test called Cologuard(R).

Exact Sciences Corp was incorporated in the State of Delaware on February 10, 1995. It is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer. The Company's Cologuard test is designed to detect pre-cancerous lesions or polyps, and each of the four stages of colorectal cancer and is expected to be a powerful, preventive tool. By detecting pre-cancers and cancers early with its test, affected patients can be referred to colonoscopy, during which the polyps or lesions can be removed. In November 2012, Company completed enrollment for its pivotal FDA clinical trial with over 10,000 patients enrolled at 90 enrollment sites in the U.S. and Canada. All patients provided a sample to be tested with Cologuard test, and received a FIT test and a colonoscopy. In addition, as part of its 2009 strategic transaction with Genzyme Corporation, it received an exclusive license back from Genzyme Corporation in the fields of colorectal cancer screening and stool-based detection of any disease or condition to the 26 patents issued and 7 pending patent applications in the U.S., and 29 patents issued and 12 pending patent applications in foreign jurisdictions sold to Genzyme. Certain of its activities are subject to regulatory oversight by the FDA under provisions of the Federal Food, Drug, and Cosmetic Act and regulations thereunder, including regulations governing the development, marketing, labeling, promotion, manufacturing and export of diagnostic products. sDNA testing faces competition from procedure-based detection technologies such as flexible sigmoidoscopy, colonoscopy and virtual colonoscopy.

Ratios

vs
industry
vs
history
P/B 4.19
EXAS's P/B is ranked lower than
66% of the 232 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.35 vs. EXAS: 4.19 )
Ranked among companies with meaningful P/B only.
EXAS' s P/B Range Over the Past 10 Years
Min: 1.65  Med: 6.58 Max: 36.44
Current: 4.19
1.65
36.44
P/S 17.63
EXAS's P/S is ranked lower than
86% of the 228 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.20 vs. EXAS: 17.63 )
Ranked among companies with meaningful P/S only.
EXAS' s P/S Range Over the Past 10 Years
Min: 9.28  Med: 44.87 Max: 1306.32
Current: 17.63
9.28
1306.32
Current Ratio 11.94
EXAS's Current Ratio is ranked higher than
95% of the 207 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.50 vs. EXAS: 11.94 )
Ranked among companies with meaningful Current Ratio only.
EXAS' s Current Ratio Range Over the Past 10 Years
Min: 1.02  Med: 8.71 Max: 50.84
Current: 11.94
1.02
50.84
Quick Ratio 11.69
EXAS's Quick Ratio is ranked higher than
95% of the 207 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.15 vs. EXAS: 11.69 )
Ranked among companies with meaningful Quick Ratio only.
EXAS' s Quick Ratio Range Over the Past 10 Years
Min: 1.02  Med: 8.57 Max: 50.84
Current: 11.69
1.02
50.84
Days Inventory 69.14
EXAS's Days Inventory is ranked higher than
58% of the 166 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 85.13 vs. EXAS: 69.14 )
Ranked among companies with meaningful Days Inventory only.
EXAS' s Days Inventory Range Over the Past 10 Years
Min: 69.14  Med: 124.58 Max: 169.5
Current: 69.14
69.14
169.5
Days Sales Outstanding 36.53
EXAS's Days Sales Outstanding is ranked higher than
85% of the 165 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 64.09 vs. EXAS: 36.53 )
Ranked among companies with meaningful Days Sales Outstanding only.
EXAS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 36.53  Med: 162.5 Max: 279.33
Current: 36.53
36.53
279.33
Days Payable 21.85
EXAS's Days Payable is ranked lower than
87% of the 157 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 58.24 vs. EXAS: 21.85 )
Ranked among companies with meaningful Days Payable only.
EXAS' s Days Payable Range Over the Past 10 Years
Min: 21.85  Med: 1526.07 Max: 249295
Current: 21.85
21.85
249295

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -14.80
EXAS's 3-Year Average Share Buyback Ratio is ranked lower than
67% of the 131 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -5.50 vs. EXAS: -14.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
EXAS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -217.1  Med: -11.9 Max: -1
Current: -14.8
-217.1
-1

Valuation & Return

vs
industry
vs
history
Price/Net Cash 5.10
EXAS's Price/Net Cash is ranked higher than
73% of the 99 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.33 vs. EXAS: 5.10 )
Ranked among companies with meaningful Price/Net Cash only.
EXAS' s Price/Net Cash Range Over the Past 10 Years
Min: 2.02  Med: 6.63 Max: 90
Current: 5.1
2.02
90
Price/Net Current Asset Value 4.77
EXAS's Price/Net Current Asset Value is ranked higher than
66% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.61 vs. EXAS: 4.77 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
EXAS' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.98  Med: 6.42 Max: 60
Current: 4.77
1.98
60
Price/Tangible Book 4.19
EXAS's Price/Tangible Book is ranked lower than
52% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.57 vs. EXAS: 4.19 )
Ranked among companies with meaningful Price/Tangible Book only.
EXAS' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.87  Med: 5.95 Max: 33.71
Current: 4.19
1.87
33.71
Price/Median PS Value 0.39
EXAS's Price/Median PS Value is ranked higher than
86% of the 212 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.02 vs. EXAS: 0.39 )
Ranked among companies with meaningful Price/Median PS Value only.
EXAS' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.24  Med: 1.46 Max: 185.2
Current: 0.39
0.24
185.2
Earnings Yield (Greenblatt) (%) -14.36
EXAS's Earnings Yield (Greenblatt) (%) is ranked lower than
65% of the 258 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.94 vs. EXAS: -14.36 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
EXAS' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -106.22  Med: 0 Max: 41.6
Current: -14.36
-106.22
41.6

More Statistics

Revenue (TTM) (Mil) $78.56
EPS (TTM) $ -1.72
Beta0.89
Short Percentage of Float25.17%
52-Week Range $4.67 - 22.80
Shares Outstanding (Mil)108.41

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 94 158 246
EPS ($) -1.73 -1.46 -0.89
EPS w/o NRI ($) -1.73 -1.46 -0.89
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for NAS:EXAS

Headlines

Articles On GuruFocus.com
Whitney Tilson's Robin Hood Conference Presentation Nov 19 2015 
Why I'm Short Exact Sciences - Whitney Tilson Presentation Feb 24 2015 
Weekly CEO Sells Highlight: Exact Sciences Corp Zayo Group Holdings Inc, Western Alliance Bancorp, a Oct 27 2014 
Meridian Funds Comments on Exact Sciences Corp Jun 20 2014 
Weekly CEO Buys Highlight: BFS, FL, BGC, AMCF, and EXAS Nov 28 2010 
EXACT Sciences Corp. (EXAS) CEO Kevin T Conroy buys 6,000 Shares Nov 23 2010 
EXACT Sciences Corp. (EXAS) CFO Maneesh Arora buys 2,500 Shares Aug 20 2010 
Weekly CFO Buys Highlight: Heska Corp., Apollo Investment Corp., EXACT Sciences Corp., Innospec Inc. Feb 28 2010 

More From Other Websites
Is Depomed Inc (DEPO) A Good Stock To Buy? Dec 02 2016
ETFs with exposure to EXACT Sciences Corp. : November 28, 2016 Nov 28 2016
Exact Sciences Grants Inducement Restricted Stock Unit Awards to Recently Hired Employees Nov 18 2016
ETFs with exposure to EXACT Sciences Corp. : November 16, 2016 Nov 16 2016
Exact Sciences Corp (EXAS) President and CEO Kevin T Conroy Sold $10.5 million of Shares Nov 16 2016
EXACT Sciences Corp. :EXAS-US: Earnings Analysis: Q3, 2016 By the Numbers : November 14, 2016 Nov 14 2016
EXACT SCIENCES CORP Files SEC form 8-K, Change in Directors or Principal Officers Nov 10 2016
Exact Sciences Appoints Jeff Elliott Chief Financial Officer Nov 08 2016
Exact Sciences to participate in November investor conferences Nov 08 2016
EXACT SCIENCES CORP Financials Nov 01 2016
Exact Sciences’ Cologuard product wins a top honor for innovation Oct 28 2016
Exact Sciences' Cologuard Wins Prestigious Prix Galien Award for Best Medical Technology Product Oct 28 2016
EXACT Sciences Corp. breached its 50 day moving average in a Bearish Manner : EXAS-US : October 27,... Oct 27 2016
Edited Transcript of EXAS earnings conference call or presentation 26-Oct-16 2:00pm GMT Oct 26 2016
EXACT SCIENCES CORP Files SEC form 10-Q, Quarterly Report Oct 26 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)